• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying

    4/26/24 7:36:41 AM ET
    $AUID
    $BHVN
    $BSVN
    $FEIM
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUID alert in real time by email

    Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    Biohaven

    • The Trade: Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey acquired a total of 25,503 shares at an average price of $39.18. To acquire these shares, it cost around $999,169.
    • What's Happening: On April 18, Biohaven priced a 5.609 million share offering at $41 per share.
    • What Biohaven Does: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.

    authID

    • The Trade: authID Inc. (NASDAQ:AUID) 10% owner Stephen Jeffrey Garchik acquired a total of 12,000 shares at an average price of $6.85. To acquire these shares, it cost around $82,200.
    • What's Happening: On March 20, authID posted a narrower FY23 loss.
    • What authID Does: AuthID Inc is a company engaged in ensuring cyber-savvy enterprises “Know Who’s Behind the Device” for every customer or employee login and transaction.

    Don’t forget to check out our premarket coverage here

    Frequency Electronics

    • The Trade: Frequency Electronics, Inc. (NASDAQ:FEIM) Director Russell M Sarachek bought a total of 1,602 shares at an average price of $9.51. To acquire these shares, it cost around $15,235.
    • What's Happening: On March 14, Frequency Electronics posted a narrower third-quarter loss.
    • What Frequency Electronics Does: Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications.

    Bank7

    • The Trade: Bank7 Corp. (NASDAQ:BSVN) Director Edward Patrick Gray bought a total of 1,000 shares at an average price of $27.25. The insider spent around $27,254 to buy those shares.
    • What's Happening: On April 12, Bank7 posted upbeat quarterly earnings.
    • What Bank7 Does: Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a wide variety of commercial and retail financial services.

    Check This Out: Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday

    Get the next $AUID alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUID
    $BHVN
    $BSVN
    $FEIM

    CompanyDatePrice TargetRatingAnalyst
    Biohaven Ltd.
    $BHVN
    2/6/2026$23.00Buy
    Goldman
    Biohaven Ltd.
    $BHVN
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    Biohaven Ltd.
    $BHVN
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    Biohaven Ltd.
    $BHVN
    11/26/2025$11.00Buy → Neutral
    UBS
    Biohaven Ltd.
    $BHVN
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    Biohaven Ltd.
    $BHVN
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    Frequency Electronics Inc.
    $FEIM
    9/18/2025$43.00Buy
    Craig Hallum
    Biohaven Ltd.
    $BHVN
    9/17/2025$28.00Buy
    Citigroup
    More analyst ratings

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

    Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations; it has also demonstrated a highly favorable safety and tolerability profile in more than 700 trial participants.In nonclinical studi

    3/19/26 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frequency Electronics, Inc. Announces Third Quarter and Fiscal Year 2026 Financial Results

    MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ("FEI" or the "Company") (NASDAQ-FEIM) is pleased to announce its financial results for the third quarter and fiscal year 2026. Revenue for the three and nine months ended January 31, 2026, was approximately $16.9 million and $47.8 million, respectively, compared to $18.9 million and $49.8 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and nine months ended January 31, 2026 was $1.3 million and $3.3 million, respectively, compared to $3.5 million and $8.5 million, respectively, reported for the same period of the previous fiscal year. Net Income from

    3/11/26 4:01:00 PM ET
    $FEIM
    Electrical Products
    Industrials

    Frequency Electronics Inc. Announces Contract Awards Valued at Approximately $45 million

    MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ("FEI" or the "Company") (NASDAQ-FEIM), a leading provider of precision timing and frequency control products for space and terrestrial applications, is pleased to announce the award of two contracts for satellite programs. One contract is in the domain of FEI's traditional space satellite programs, and one is part of the new proliferated satellite paradigm. The contracts are valued at approximately $45 million on a combined basis, and the Company expects that this new business will begin to enter funded backlog in this current fiscal fourth quarter of 2026. Further, FEI anticipates additional awards of sim

    3/11/26 4:01:00 PM ET
    $FEIM
    Electrical Products
    Industrials

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00

    1/21/26 8:29:40 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Biohaven from Buy to Neutral and set a new price target of $11.00

    12/3/25 7:48:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Travis Thomas L sold $240,000 worth of shares (6,000 units at $40.00), decreasing direct ownership by 2% to 272,101 units (SEC Form 4)

    4 - Bank7 Corp. (0001746129) (Issuer)

    3/9/26 4:39:44 PM ET
    $BSVN
    Major Banks
    Finance

    SEC Form 4 filed by Chief Financial Officer Buten Matthew

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:09:03 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUID
    $BHVN
    $BSVN
    $FEIM
    SEC Filings

    View All

    SEC Form 10-Q filed by Frequency Electronics Inc.

    10-Q - FREQUENCY ELECTRONICS INC (0000039020) (Filer)

    3/17/26 12:22:49 PM ET
    $FEIM
    Electrical Products
    Industrials

    SEC Form NT 10-K filed by Bank7 Corp.

    NT 10-K - Bank7 Corp. (0001746129) (Filer)

    3/16/26 8:44:51 PM ET
    $BSVN
    Major Banks
    Finance

    SEC Form DEFA14A filed by Biohaven Ltd.

    DEFA14A - Biohaven Ltd. (0001935979) (Filer)

    3/13/26 4:57:48 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jisser Ken bought $50,406 worth of shares (40,650 units at $1.24), increasing direct ownership by 79% to 92,125 units (SEC Form 4)

    4 - authID Inc. (0001534154) (Issuer)

    11/26/25 8:00:31 AM ET
    $AUID
    Computer Software: Prepackaged Software
    Technology

    Director Garchik Stephen Jeffrey bought $216,500 worth of shares (126,608 units at $1.71) (SEC Form 4)

    4 - authID Inc. (0001534154) (Issuer)

    11/24/25 4:10:09 PM ET
    $AUID
    Computer Software: Prepackaged Software
    Technology

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Financials

    Live finance-specific insights

    View All

    Frequency Electronics, Inc. Announces Third Quarter and Fiscal Year 2026 Financial Results

    MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ("FEI" or the "Company") (NASDAQ-FEIM) is pleased to announce its financial results for the third quarter and fiscal year 2026. Revenue for the three and nine months ended January 31, 2026, was approximately $16.9 million and $47.8 million, respectively, compared to $18.9 million and $49.8 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and nine months ended January 31, 2026 was $1.3 million and $3.3 million, respectively, compared to $3.5 million and $8.5 million, respectively, reported for the same period of the previous fiscal year. Net Income from

    3/11/26 4:01:00 PM ET
    $FEIM
    Electrical Products
    Industrials

    Frequency Electronics Announces Third Quarter Fiscal 2026 Financial Results Conference Call: Wednesday, March 11, 2026, at 4:30 PM ET

    MITCHEL FIELD, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ:FEIM), will hold a conference call to discuss results for the third quarter of its fiscal year 2026, ended January 31, 2026, on Wednesday, March 11, 2026, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency's web site at www.freqelec.com. Investors and analysts may also access the call by dialing 888-506-0062. International callers may dial 973-528-0011. Callers should provide participant access code: 118136 or ask for the Frequency Electronics conference call. A telephone replay of the archived call wi

    3/9/26 4:01:00 PM ET
    $FEIM
    Electrical Products
    Industrials

    Bank7 Corp. Declares Quarterly Cash Dividend on Common Stock

    OKLAHOMA CITY, March 5, 2026 /PRNewswire/ -- Bank7 Corp. (NASDAQ:BSVN), the parent company of Oklahoma City-based Bank7, today announced the declaration of a quarterly cash dividend of $0.27 per share on its outstanding common stock. The dividend will be paid on April 3, 2026, to shareholders of record as of the close of business on March 19, 2026. About Bank7 Corp. We are Bank7 Corp., a bank holding company headquartered in Oklahoma City, Oklahoma. Through our wholly-owned subsidiary, Bank7, we operate twelve full-service branches in Oklahoma, the Dallas/Fort Worth, Texas metro

    3/5/26 9:00:00 AM ET
    $BSVN
    Major Banks
    Finance

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/12/24 1:20:24 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/4/24 11:16:33 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUID
    $BHVN
    $BSVN
    $FEIM
    Leadership Updates

    Live Leadership Updates

    View All

    authID Announces its 2025 Board of Directors Nominees Ahead of Annual Meeting

    Highly Qualified New Board Nominees Will Strengthen authID's mission to Drive Growth and Value Creation for Shareholders 2025 Annual Meeting to be Held on June 26, 2025 DENVER, May 27, 2025 (GLOBE NEWSWIRE) -- authID® (NASDAQ:AUID)("authID" or the "Company"), a leading provider of biometric identity verification and authentication solutions, is nominating four highly qualified executives to the Board of Directors (the "Board"), in addition to the nomination of existing directors, included within the 2025 Proxy Statement filed on May 16, 2025. The 2025 Annual Meeting will be held virtually on June 26, 2025, at 10.00 a.m. EDT.  The following new Board nominees will be up for election at

    5/27/25 8:00:00 AM ET
    $AUID
    $KNBE
    Computer Software: Prepackaged Software
    Technology

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frequency Electronics, Inc. Announces Appointment of Tom McClelland to the Board of Directors

    MITCHEL FIELD, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ("FEI" or the "Company") (NASDAQ-FEIM) today is pleased to announce the appointment of its Chief Executive Officer, Dr. Thomas McClelland, to the Company's Board of Directors, effective immediately. Tom, a 40-year veteran of FEI, served as the Company's Interim President and CEO from July 8, 2022 through January 17, 2023, and has served as permanent President and CEO since then. Prior to that, Tom served as FEI's Chief Scientist and has led the Company's research and scientific efforts for over 20 years. He is one of the foremost experts in precision timing and space-related applications. He has the highest

    12/5/24 8:30:00 AM ET
    $FEIM
    Electrical Products
    Industrials